EcoDrugPlus

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSPKIG00000005211
Gene Symbol: LOC111835941
2 Cross references
107 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSPKIG00000011142
Gene Symbol: LOC111836076
4 Cross references
325 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSPKIG00000006914
Gene Symbol: LOC111855741
3 Cross references
259 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSPKIG00000003717
Gene Symbol: LOC111835923
3 Cross references
259 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSPKIG00000023338
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSPKIG00000010153
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSPKIG00000024120
Gene Symbol: P2RY2
1 Cross references
197 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSPKIG00000019654
Gene Symbol: LOC111855422
3 Cross references
199 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSPKIG00000007574
Gene Symbol: LOC111851986
2 Cross references
198 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSPKIG00000018197
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSPKIG00000024152
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSPKIG00000011521
Gene Symbol: LOC111850223
4 Cross references
251 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).